Curis | CRIS - Sales Revenues


Curis reported $1.14M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Bayer EUR 11.44B 1.78B Dec/2025
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Curis USD 1.14M 1.41M Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Exelixis USD 610.8M 12.14M Mar/2026
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Merck USD 16.29B 110M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Takeda JPY 1.19T 80B Dec/2025
TG Therapeutics USD 194.8M 2.23M Mar/2026
Verastem USD 17.54M 7.53M Dec/2025
Xoma USD 25K 5M Sep/2024